Use of TRAIL polypeptides to induce apoptosis

Details Use of TRAIL polypeptides to induce apoptosis Use of TRAIL polypeptides to induce apoptosis

2008-08-21

2010-06-15

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

07736637

ABSTRACT:
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

REFERENCES:
patent: 5512435 (1996-04-01), Renschler et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5876954 (1999-03-01), Perron et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 6444640 (2002-09-01), Nagane et al.
patent: 6740739 (2004-05-01), Ashkenazi et al.
patent: 6746668 (2004-06-01), Ashkenazi
patent: 6998116 (2006-02-01), Ashkenazi
patent: 7285533 (2007-10-01), Ashkenazi
patent: 2002/0115613 (2002-08-01), Kumar
patent: 2007/0036782 (2007-02-01), Ashkenazi
patent: 2009/0162364 (2009-06-01), Ashkenazi
patent: WO-9518819 (1995-07-01), None
patent: WO-9725428 (1997-07-01), None
patent: WO-97/33899 (1997-09-01), None
patent: WO-9746686 (1997-12-01), None
patent: WO-99/07408 (1999-02-01), None
patent: WO-9907408 (1999-02-01), None
patent: WO-9936535 (1999-07-01), None
patent: WO-9948527 (1999-09-01), None
Beers et al., The Merck Manual of Diagnosis and Therapy, 17th ed., pp. 986-995 (1999).
Beers and Berkow, The Merck Manual of Diagnosis and Therapy, 17th edition, pp. 955-962 (1999).
Beutler B. and Cerami A., “Cachectin and tumour necrosis factor as two sides of the same biological coin,”Nature 320: 584, 1986.
Gruss H.J. and Dower S.K., “Tumor Necrosis Factor Ligand Superfamily: involvement in the pathology of malignant lymphomas,”Blood 85(12): 3378-3404, Jun. 15, 1995.
Locksley et al., “The TNF and TNF receptor superfamilies: Integrating mammalian biology,”Cell 104: 487-501, 2001.
Wang et al., “Molecular cloning of the complementary DNA for human tumor necrosis factor,”Science 228:149, 1985.
Ware, et al., “The ligands and receptors of the lymphotoxin system,”Current Topics in Microbiology and lmmunology 198: 175-218, 1995.
Notice of Opposition to European Patent 0835305 titled “Cytokine that induces Apoptosis” (Immunex Corporation) filed by National University of Ireland, Galway.
Banner et al., “Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation,”Cell 73: 431-445, 1993.
Bell, G.I. and Takeda, J., NCBI databank record, accession No. T10524, Jul. 28, 1993.
Belliveau et al., “Presence of the cytokine APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Society for Neuroscience Abstracts 23(1-2). 1997; p. 2207.
Belliveau et al., “Presence of the cytokine, APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Poster presented at the 27thAnnual Meeting of the Society for Neuroscience, Oct. 25-30, 1997, New Orleans.
Beutler and van Huffel, “Unraveling function in the TNF ligand and receptor families,”Science 264: 667-668, 1994.
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science 247: 1306-1310, 1990.
Genexpress, NCBI databank record, accession No. Z36726, Aug. 18, 1994.
Goodwin et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor,”Eur. J. lmmunol. 23: 2631-2641, 1993.
Goodwin et al., “Study of the structure and function of Trail, a new member of the TNF ligand family,”Eur. Cytokine Network 7(2): 166, 1996.
Hillier et al., NCBI databank record, accession No. T90422, Mar. 20, 1995.
Hillier et al., NCBI databank record, accession No. T82085, Mar. 10, 1995.
Hillier et al., NCBI databank record, accession No. R31020, Apr. 28, 1995.
Hollenbaugh et al., “Construction of immunoglobulin fusion proteins,”Current Protocols in Immunology, Supp. 4, 1992, 10.19.1-10.19.11.
Hoppe et al., “A parallel three stranded α-helical bundle at the nucleation site of collagen triple-helix formation,”FEBS Letters 344: 191-195, 1994.
Jo, M. et al., “Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand,”Nature Medicine 6: 564-567, May 2000.
Kroemer, “The pharmacology of T cell apoptosis,”Adv. lmmunol. 58: 211-296, 1995.
Landschultz, et al., “The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins,”Science 240: 1759-1764, 1988.
Marsters et al., “Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA,”Current Biology 6(6): 750, 1996.
Menard et al., “A gliotoxic factor and multiple sclerosis,”J Neurological Sciences 154: 209-221, 1998.
O'Mahoney et al., “An immune suppressive factor derived from esophageal squamous carcinom induces apoptosis in normal and transformes cells of lymphoid lineage,”J. Immunol. 151(9): 4847-4856, 1993.
Pitti et al., “Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family,”J. Biol. Chem. 271(22): 12687-12690, 1996.
Rieger, F. and J. Belliveau, report on research studies, in letter dated Aug. 31, 1999.
Rieger, R. et al., Glossary of Genetics and Cytogenetics, Fourth Ed., Springer-Verlag, pp. 16-19, 1976.
Sachs and Lotem, “Control of programmed cell death in normal and leukemic cells: new implications for therapy,”Blood 82(1): 15-21, 1993.
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death,”Cell 76: 959-962, 1994.
Smith et al., “CD30 Antigen, a marker for Hodgkin's Lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF,”Cell 73: 1349-1360, 1993.
Smith et al., “Trail: a new member of the TNF ligand family that induces apoptosis,”Eur. Cytokine Network 7(3): 429, 1996.
Suda et al., “Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family,”Cell 75: 1169-1178, 1993.
Takahashi et al., “Human Fas ligand: gene structure, chromosomal location and species specificity,”International Immunol. 6(10): 1567-1574, 1994.
Takeda et al., “A molecular inventory of human pancreatic islets: sequence analysis of 1000 cDNA clones,”Human Molecular Genetics 2(11): 1793-1798, 1993.
Wiley et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,”Immunity 3:673-682, 1995.
Wong et al., “Antiviral properties of TNF,” inTumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Raven Press, Ltd., New York, 1992, 371-381.
Mikayama et al., Proc. Natl. Acad. Sci. USA, 90:10056-10060 (1993).
Voet et al., Biochemistry, John Wiley & Sons, Inc. pp. 126-128 and 228-234 (1990).
Berg et al. “Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L,” Cell Death and Differentiation 14:2021-2034 (2007).

Affiliated with

Also associated with

Rating

Use of TRAIL polypeptides to induce apoptosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of TRAIL polypeptides to induce apoptosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of TRAIL polypeptides to induce apoptosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4165560